波音游戏-波音娱乐城赌球打不开

Vitargent - Pioneer in toxicity testing technology

Dr Chen Xueping gives a presentation on the zebrafish embryo testing for whitening essence of skincare products. Dr Chen Xueping gives a presentation on the zebrafish embryo testing for whitening essence of skincare products.

Established in 2010, Vitargent is a pioneer in the field of safety testing technology by using medaka and zebrafish embryos to perform toxicity tests. Clients include global cosmetics and skincare companies, food and beverage conglomerates, leading testing laboratories and governments. Vitargent was awarded the Grand Prix at the International Exhibition of Inventions of Geneva in 2015.

A PhD graduate in environmental toxicology from City University of Hong Kong (CityUHK), Dr Chen Xueping is the co-founder and Chief Technology Officer of Vitargent (International) Biotechnology Limited (Vitargent). She is a registered toxicologist in the United Kingdom and Europe.

Vitargent was established in 2010 by Dr Chen Xueping and Eric Chen, another CityUHK alumni. It is a pioneer in the field of safety testing technology, employing patented CityUHK technology that uses transgenic medaka fish and zebrafish embryos to detect estrogenic endocrine disruptors and test for up to 1,000 toxicants within 24 to 48 hours across products. It has the only ISO17025 accredited laboratory in Asia that provides fish embryo-based toxicity testing.


Vitargent was awarded the Grand Prix at the International Exhibition of Inventions of Geneva in 2015. The company’s core members (from left): Dr Chen Xueping, Mr Eric Chen, Mr Jimmy Tao and Mr Jeffrey Cheung. Vitargent was awarded the Grand Prix at the International Exhibition of Inventions of Geneva in 2015. The company’s core members (from left): Dr Chen Xueping, Mr Eric Chen, Mr Jimmy Tao and Mr Jeffrey Cheung. (Photo source: Dr Chen Xueping)

Vitargent has received funding support from CityUHK, the Hong Kong government’s Innovation and Technology Fund and the Hong Kong Science and Technology Parks Corporation’s (HKSTP) Incu-Bio programme, and financing from various investors. Having established a research base in HKSTP since 2011, it now employs nearly 60 people. The Hong Kong team focuses on R&D, while their colleagues in mainland China are responsible for business development and information technology. The biotechnology company has developed projects with the governments of Beijing, Shanghai, Guangdong and Shenzhen, including the joint establishment of laboratories, testing platforms and product databases. It also plans to set up its own laboratory in mainland China.

Following the changes in the social and business environment, Vitargent has gradually changed its focus from ensuring product safety to supporting corporates in reducing the use of toxic raw materials and enhancing product quality.

Meanwhile, China began to implement the new “Regulations on the Supervision and Administration of Cosmetics” in 2021, which marks the first reform of the country’s cosmetics industry in some 30 years. Authorities, industry associations and manufacturers need efficient and effective ways to ensure that products and regulations adhere to international standards, and they are more open to accepting new technologies. “Our technology enables manufacturers to ensure their products are free of harmful chemicals, gives consumers the information they need to make safer choices. We vow to become a global leader and standard-setter in the field of safety testing.”

Dr Chen acknowledges that investors are very interested in Vitargent, with further financing, acquisition and listing opportunities made available. “If we’re not determined to pursue excellence in our technology, we might well consider these propositions, and I would have been retired by now,” Dr Chen says. While Vitargent continues to pursue the goal of becoming a unicorn, it further develops its technology to limit the amount of pollutants during the manufacturing process and fulfills its social responsibility to protect the environment.

The first-in-the-world bio testing technology was entirely CityUHK-oriented, pioneered by Professor Cheng Shuk Han, Chair Professor at the Department of Biomedical Sciences. Dr Chen feels deeply grateful to Professor Cheng for her guidance during her PhD study and post-doc fellow research, and to CityUHK for the international exposure given. That has enabled her to stay enthusiastic in life sciences, and made great strides in scientific research and entrepreneurship.

She is confident that the HK Tech 300 programme can help CityUHK students and youth to strength their innovation and entrepreneurship skills, supporting their entrepreneurship journey.

“Entrepreneurship is like crossing a river by feeling the stones. Keep a clear head and always reflect. Work hard to achieve your goal. No matter how many challenges you face, there are always more solutions than problems. You’ll succeed in seeking what you want if you persist long enough,” Dr Chen adds.

(May 2021)

 

Back to top
嘉定区| 百家乐筹码片| 百家乐庄闲的几率| 白金国际| 金逸太阳城团购| 在线百家乐| 联众百家乐的玩法技巧和规则| 全南县| 网上百家乐哪里| 百家乐赌场赌场网站| 大发888开户送58| 百家乐官网网络赌博网址| 澳门百家乐官网怎么| 百家乐的如何玩| 大发888官网 平台| 百家乐官网买隔一数| 赌百家乐的方法| 太阳城百家乐怎么出千| 百家乐波音独家注册送彩| 百家乐官网技巧论坛| 百家乐押注方法| 澳门百家乐官网免费开户| 百家乐官网规| 长沙百家乐的玩法技巧和规则| 百家乐官网线上游戏| 真人百家乐分析软件是骗局| 在线赌博| E世博百家乐官网娱乐城| 百家乐游戏平台有哪些哪家的口碑最好 | 百家乐偷码| bet365注册 jxhymp| 百家乐官网筹码币方形| 曼哈顿百家乐的玩法技巧和规则| 百家乐官网怎样做弊| 老人头百家乐的玩法技巧和规则| 巴东县| 如何看百家乐官网的玩法技巧和规则 | 百家乐投注哪个信誉好| 现金百家乐| 足球百家乐网上投注| 百家乐官网接线玩法|